US6756038B1
(en)
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
WO2001024832A2
(de)
*
|
1999-09-27 |
2001-04-12 |
Gabriele Pecher |
Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
|
DE60038971D1
(de)
*
|
1999-10-22 |
2008-07-03 |
Aventis Pasteur |
Verfahren zur erregung und/oder verstärkung der immunantwort gegen tumorantigene
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
US7449557B2
(en)
|
2000-06-02 |
2008-11-11 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
AU2001278330A1
(en)
*
|
2000-07-31 |
2002-02-13 |
Aventis Pasteur Limited |
Modified CEA and uses thereof
|
AU2001288682A1
(en)
|
2000-08-30 |
2002-03-13 |
Chemocentryx, Inc. |
Inhibition of cmv infection and dissemination
|
EP1320620B1
(en)
|
2000-09-25 |
2015-01-21 |
The Regents Of The University Of Michigan |
Production of viral vectors
|
WO2002062296A2
(en)
|
2001-02-02 |
2002-08-15 |
Chemocentryx, Inc. |
Methods and compositions useful for stimulating an immune response
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
AU2003301021C1
(en)
|
2002-12-16 |
2010-02-18 |
Globelmmune, Inc. |
Yeast-based vaccines as immunotherapy
|
JP2007503834A
(ja)
*
|
2003-09-05 |
2007-03-01 |
サノフィ パストゥール リミテッド |
黒色腫用の多抗原ベクター
|
CA2550583C
(en)
*
|
2003-10-08 |
2013-01-15 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
JP5285855B2
(ja)
|
2003-11-12 |
2013-09-11 |
アメリカ合衆国 |
膵癌を処置および予防するためのカスタムベクター
|
ES2476990T3
(es)
*
|
2003-11-12 |
2014-07-15 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Sistema para tratar y prevenir cáncer de mama
|
WO2005068640A2
(en)
*
|
2003-12-23 |
2005-07-28 |
Aventis Pasteur, Inc. |
Modified ksa and uses thereof
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
KR100790646B1
(ko)
*
|
2004-07-03 |
2008-01-02 |
재단법인 목암생명공학연구소 |
세포매개 면역반응을 효과적으로 유도하는 hcv수퍼타입 에피토프, 그를 코딩하는 올리고뉴클레오타이드및 그의 용도
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
EP2141997B1
(en)
|
2007-03-30 |
2012-10-31 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
|
ES2725450T3
(es)
|
2007-07-02 |
2019-09-24 |
Etubics Corp |
Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
|
DK2207564T3
(en)
*
|
2007-10-18 |
2017-01-16 |
Bavarian Nordic As |
USE OF VAT FOR TREATMENT OF PROSTATACANCES
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
JP5588990B2
(ja)
*
|
2008-10-31 |
2014-09-10 |
トレムアールエックス, インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
JP5759980B2
(ja)
*
|
2009-04-17 |
2015-08-05 |
グローブイミューン,インコーポレイテッド |
癌および感染症に対する免疫療法組成物の組み合わせ
|
WO2013025972A1
(en)
|
2011-08-17 |
2013-02-21 |
Globeimmune, Inc. |
Yeast-muc1 immunotherapeutic compositions and uses thereof
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
KR20210054067A
(ko)
|
2013-06-14 |
2021-05-12 |
싸이오서스 테라퓨틱스 엘티디. |
유형 b 아데노바이러스에 대한 투여 요법 및 제형
|
SG11201602887QA
(en)
|
2013-10-25 |
2016-05-30 |
Psioxus Therapeutics Ltd |
Oncolytic adenoviruses armed with heterologous genes
|
SI3074517T1
(sl)
*
|
2013-11-28 |
2021-12-31 |
Bavarian Nordic A/S |
Sestavki in postopki za spodbujanje izboljšanega imunskega odziva z uporabo vektorjev poksvirusa
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス, インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
AU2016205215B2
(en)
*
|
2015-01-09 |
2021-03-11 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
KR20170102002A
(ko)
|
2015-01-09 |
2017-09-06 |
이투빅스 코포레이션 |
에볼라 바이러스 백신접종을 위한 방법 및 조성물
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
CN108396015B
(zh)
|
2015-04-30 |
2022-02-18 |
皮斯奥克斯治疗公司 |
编码b7蛋白质的溶瘤腺病毒
|
KR20180107105A
(ko)
|
2015-12-17 |
2018-10-01 |
싸이오서스 테라퓨틱스 엘티디. |
항-tcr-복합체 항체 또는 단편을 암호화하는 군 b 아데노바이러스
|
KR20180118198A
(ko)
*
|
2016-03-18 |
2018-10-30 |
난트셀, 인크. |
수지상 세포 감염을 위한 멀티모달 벡터(multimodal vector for dendritic cell infection)
|
US20200282032A1
(en)
*
|
2016-05-27 |
2020-09-10 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
WO2020061203A1
(en)
|
2018-09-21 |
2020-03-26 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|